×
About 15,175 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  3,783 results

DNA methylation and transcriptome signatures of the PDCD1 gene in ankylosing spondylitis.
https://doi.org/10.1038/s41435-023-00196-w
Genes and Immunity; Wu Y, Chen Y et. al.

Jan 29th, 2023 - Ankylosing spondylitis (AS) is an autoimmune-related inflammatory arthritis. The association between the DNA methylation and mRNA expression of PDCD1 gene with the susceptibility to AS remains unclear. In this case-control study, the methylation l...

PsA-related uveitis: Real-world data on epidemiology and clinical features
https://www.mdedge.com/rheumatology/article/260852/psoriatic-arthritis/psa-related-uveitis-real-world-data-epidemiology-and

Jan 26th, 2023 - Key clinical point: Uveitis related to psoriatic arthritis (PsA) had a prevalence of approximately 5%, presented as an acute and recurrent disease with anterior and unilateral involvement, and was associated with impaired quality of life and incre.

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries
https://clinicaltrials.gov/ct2/show/NCT02281747

Jan 26th, 2023 - Major orthopedic procedures, including total joint replacement and spine surgeries, are among the most common procedures in the population. Learning about how often these surgeries are performed can give indications of whether the treatment of art...

Progression of Spinal Fusion in Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT00085995

Jan 26th, 2023 - Spinal fusion is the clinical, radiological, and pathological hallmark of ankylosing spondylitis (AS). However, spinal fusion occurs slowly in AS. Serial radiographs rarely show changes over 2 years, and often 5 or more years are needed to demonst...

2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis,...
https://clinicaltrials.gov/ct2/show/NCT05155098

Jan 26th, 2023 - After the baseline visit, data will be collected for each patient prospectively every 6 months for up to 2 years. At each visit, effectiveness parameters, as well as the patients' QoL and treatment pattern will be documented.

see more →

Guidelines  11 results

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients ...
https://www.ncbi.nlm.nih.gov/pubmed/30717501
Pain Physician; Kaye AD, Manchikanti L et. al.

Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...

The effectiveness, safety, and economic evaluation of Korean medicine for unexplained i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779787
Medicine

Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
https://doi.org/10.1136/annrheumdis-2016-210770
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.

Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...

EULAR recommendations for cardiovascular disease risk management in patients with rheum...
https://doi.org/10.1136/annrheumdis-2016-209775
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.

Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...

see more →

Drugs  1,031 results see all →

Clinicaltrials.gov  388 results

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries
https://clinicaltrials.gov/ct2/show/NCT02281747

Jan 26th, 2023 - Major orthopedic procedures, including total joint replacement and spine surgeries, are among the most common procedures in the population. Learning about how often these surgeries are performed can give indications of whether the treatment of art...

Progression of Spinal Fusion in Ankylosing Spondylitis
https://clinicaltrials.gov/ct2/show/NCT00085995

Jan 26th, 2023 - Spinal fusion is the clinical, radiological, and pathological hallmark of ankylosing spondylitis (AS). However, spinal fusion occurs slowly in AS. Serial radiographs rarely show changes over 2 years, and often 5 or more years are needed to demonst...

2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis,...
https://clinicaltrials.gov/ct2/show/NCT05155098

Jan 26th, 2023 - After the baseline visit, data will be collected for each patient prospectively every 6 months for up to 2 years. At each visit, effectiveness parameters, as well as the patients' QoL and treatment pattern will be documented.

Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan
https://clinicaltrials.gov/ct2/show/NCT05609643

Jan 26th, 2023 - Axial spondyloarthritis (axSpA), which encompasses radiographic axSpA (r-axSpA, also known as ankylosing spondylitis [AS]) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. This study will assess how effective Rinv...

Reliability of IBP Criteria & Activity Scores in Patients With AxSpA
https://clinicaltrials.gov/ct2/show/NCT05327140

Jan 25th, 2023 - Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease that affects the axial skeleton mainly leading to significant pain and disability. Early diagnosis of AxSpA is important for better management of symptoms and to limit spinal damage...

see more →

News  831 results

PsA-related uveitis: Real-world data on epidemiology and clinical features
https://www.mdedge.com/rheumatology/article/260852/psoriatic-arthritis/psa-related-uveitis-real-world-data-epidemiology-and

Jan 26th, 2023 - Key clinical point: Uveitis related to psoriatic arthritis (PsA) had a prevalence of approximately 5%, presented as an acute and recurrent disease with anterior and unilateral involvement, and was associated with impaired quality of life and incre.

TNFi raises the risk for septic arthritis in seropositive RA
https://www.mdedge.com/rheumatology/article/260778/rheumatoid-arthritis/tnfi-raises-risk-septic-arthritis-seropositive-ra

Jan 24th, 2023 - Key clinical point: Tumor necrosis factor inhibitors (TNFi) increased the risk for septic arthritis in patients with seropositive rheumatoid arthritis (RA), with higher incidences within 1 year of initiating TNFi. Major finding: Patients with sero.

Phase III Trials Back Bimekizumab for Spondyloarthritis
https://www.medpagetoday.com/rheumatology/arthritis/102660

Jan 17th, 2023 - Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said. With nearly 600 patients enrolled in two parallel phase III trials, 45% a...

Axial PsA: A distinct phenotype not to be confused with ankylosing spondylitis+psoriasis
https://www.mdedge.com/rheumatology/article/260157/psoriatic-arthritis/axial-psa-distinct-phenotype-not-be-confused

Dec 14th, 2022 - Key clinical point: Axial psoriatic arthritis (PsA) can be categorized as a distinct subtype of PsA because it exhibits clinical and radiological symptoms that are different from those of ankylosing spondylitis (AS) with psoriasis. Major finding:.

Xeljanz Cancer Risks Detailed
https://www.medpagetoday.com/rheumatology/generalrheumatology/102106

Dec 7th, 2022 - The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study. Tofacitinib at either 5 or 10 mg twice ...

see more →

Patient Education  26 results see all →